| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Pediatrics, University Medical Center Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands;
Department of Anatomy and Embryology, Maastricht University, P.O. Box 616, 6200 MD Maastricht,TheNetherlands
 |
Abstract |
|---|
 Top Abstract NeurulationNeural Tube Defects (NTD)NTDThe Aetiology Of NTDPrevention Of NTDFolateHomocysteine MetabolismDisturbed Homocysteine and...Summary and Concluding RemarksReferences |
|---|
Key Words: homocysteine • folate • neural tube defects • MTHFR • metabolism
|
Neurulation |
|---|
|
TopAbstractNeurulationNeural Tube Defects (NTD)NTDThe Aetiology Of NTDPrevention Of NTDFolateHomocysteine MetabolismDisturbed Homocysteine and...Summary and Concluding RemarksReferences |
|---|
Primary Neurulation-Neural Folding.
Primary neurulation concerns the transformation of a flat neural plate into the cylindrical neural tube and involves several processes that overlap both spatially and temporally. The involved morphogenetic processes have been reviewed elsewhere (1–4); they are illustrated in Figure 1
and will be briefly described below.
|
top), while its cells increase in height and become pseudostratified. The earliest part of the neural plate consists only of tissue that will develop into the forebrain, mid-brain, and the most rostral part of the hindbrain, while later parts will become the remainder of the hindbrain and spinal cord.
The next process, shaping of the neural plate, takes place shortly after the neural plate is formed. The configuration of the plate changes, particularly due to extension in longitudinal direction and narrowing in transverse direction at the same time (Fig. 1B), a process that is referred to as convergent extension. This is the result of a combination of cellular processes: the epithelial cells increase in number, in cellular height, and in mutual positions (7, 8).
Next, the neural plate starts to bend, which begins during the process of shaping. It involves the formation of hinge points, elevation of the neural walls, and the formation and convergence of the neural folds.
Due to the formation of the medial hinge point, a medial V-shaped depression in the neural plate arises over its length (Fig. 1B), as follows. The medial neural plate cells (floor plate) decrease in height and become markedly wedge-shaped in reaction to the underlying notochord (9–11). The mechanism of wedging is suggested to involve basal expansion by withdrawing cells from the cell cycle, resulting in basally positioned nuclei (12).
The next process is elevation, whereby the lateral neural plate halves move upward and form the walls of the neural groove (Fig. 1A). Several factors are proposed to generate or facilitate this process: (i) the medial hinge point is thought to at least facilitate bending of the neural plate in its midline; and (ii) the above mentioned process of convergent extension is suggested to force the lateral neural plate halves in an upward direction by buckling (3, 13) and, by contraction of microfilament bundles, which are arranged like a purse string around the cellular apex. All neural plate cells become slightly wedge-shaped (Fig. 1C) and as a result, the whole neural plate curls up (4, 14–19). Expansion of the mesoderm, which is underneath the neural walls, likely facilitates elevation as well (Fig. 1B) (18, 19).
The next process is convergence, or medial bending, of the neural folds. The neural folds comprise the dorsal extensions of the neural walls plus the ectoderm. In the region of the future brain and of the caudal spinal cord, hinge points arise at a dorsolateral position in both neural walls. These hinge points are the likely result of interaction between the neural wall and the adjacent ectoderm, and it is proposed that they are based on enhanced apical microfilament contraction. With the formation of the dorsolateral hinge points, two longitudinal furrows arise, allowing the neural folds to bend medially until they approach each other (Fig. 1B). This neural fold convergence is possibly facilitated by the expansion of ectoderm, as caused by changes in ectodermal cell number, shape and position (20, 21). Thus, bending of the neural plate is facilitated by the median and dorsolateral hinge points around which the neural plate elevates and converges, respectively. In the somitic region, dorsolateral hinge points are not formed, and elevation alone allows the neural walls to clap shut like a book.
The last process of primary neurulation involves the closure of the neural groove with formation of the roof plate of the neural tube, the neural crest, and the overlying surface epithelium. When the neural folds have approached each other, they adhere and subsequently fuse. Such closure is effectuated by cell adhesion molecules, which are expressed at the neuroepithelial cell surface and by protrusive activity of the cells.
The initial fusion has long been proposed to occur according to the elevation-convergence-fusion concept, as depicted above. However, this sequence merely applies to progression of closure in longitudinal direction. Initial closure resembles the process as seen in between somites: the neural walls align parallelly, adhere, the adhesions release ventrally, allowing a lumen to arise, while the adhesion remains dorsally and changes into fusion (22). In this manner, no initial misalignment of the neural folds is possible, as would be by the process of convergence.
The first fusion of neural folds occurs in the high cervical region, leaving large neural tube openings called the anterior and posterior neuropore at both extremities. Previously, this fusion initiation point was considered to be the only one, and closure was thought to proceed until the anterior and posterior neuropore were closed. However, Golden and Chernoff (23, 24) showed in three mouse strains the presence of at least four different closure initiation sites plus five transient neuropores, and this was confirmed in other animal models (19, 25). In humans, such a multisite closure pattern was suggested to occur as well (26, 27) (Fig. 2). Closure 1 regards the cervical one mentioned above. Closure 2 takes place at the forebrain-midbrain transition and, like closure 1, proceeds bidirectionally, dividing the anterior neuropore in a forebrain and a mid/hindbrain neuropore. Closure 3 is unidirectional, beginning adjacent to the stomodeum and proceeding caudally to meet closure 2, thereby closing the forebrain neuropore. Finally, closure 4 takes place were it meets closure 2 to close the mid/hindbrain neuropore. The posterior neuropore is closed by caudal continuation of closure 1 and remains longest. Primary neurulation is completed after the closure of this neuropore in the sacral region (28–30).
|
Caudally of the previous posterior neuropore the caudal eminence (tail bud) is formed. This eminence arises as a continuation of the organizer and is an ectoderm-covered mass of undifferentiated mesenchymal cells. This seemingly homogeneous tissue gives rise to various tissues including the tail hindgut, somites and their derivatives, neural crest cells, and a neural cord. This cord is transferred into a neural tube without the intermediate phase of a neural plate, and becomes subsequently connected to the primary neural tube, as follows. The peripheral cells of the neural cord arrange radially and differentiate from a mesenchymal into an epithelial form. In between the central undifferentiated cells, small caveoles begin to develop that coalesce and enlarge into a canal. Now the secondary neural tube has arisen. The lumen of the primary neural tube proceeds caudally and makes contact with the newly formed lumen of the secondary neural tube. The process of canalization continues until approximately the seventh week after conception, when retrogressive differentiation begins. At the end of the embryonic period the neural cord still reaches to the end of the vertebral column, but during the fetal period it ascends to the sacral and then to lumbar levels.
|
Neural Tube Defects (NTD) |
|---|
|
TopAbstractNeurulationNeural Tube Defects (NTD)NTDThe Aetiology Of NTDPrevention Of NTDFolateHomocysteine MetabolismDisturbed Homocysteine and...Summary and Concluding RemarksReferences |
|---|
The term NTD applies to malformation of the embryonic brain and/or spinal cord. The various forms of NTD are characterized by incomplete development of the central nervous system and its closely related surrounding structures. As previously discussed, neurulation relies on many morphogenetic processes and both genetic and environmental factors are involved. Disturbances of any of these factors and processes may result in neural tube closure defects, which become manifest primarily as anencephaly or as spina bifida with myeloschisis and are accompanied by alterations of the axial skeleton, as well as the overlying meningovascular and dermal tissues (canalization). Although NTD are among the most common congenital malformations, little is understood about the underlying developmental mechanisms.
Clinically, the term spina bifida is used collectively and includes malformations with cord involvement. When NTD are subdivided according to their underlying defect, two main categories emerge: open NTD and closed NTD. In the former category, the neural tube is open due to nonclosure or to reopening of a closed tube. This defect results in the exposure of neural tissue at the surface and thus neurological damage to the child. This form of NTD is known as exencephaly if the cranial region is affected and it is known as myeloschisis (spina bifida aperta) if the caudal part is affected. Closed NTD are distinguished from the open NTD not only by their caudal locus, but also particularly by the presence of intact skin over the lesions. The medullary cone is usually prolonged and the terminal filum is thickened. Vertebral defects occur in 85% to 90% of cases with closed NTD and consist most commonly of laminar defects over several segments; other skeletal abnormalities include a widened spinal canal and sacral deformities (34, 36). About 80% of cases exhibit a dermal lesion in the lumbrosacral area, consisting of abnormal collections of hair, cutaneous dimples or tracts, superficial cutaneous abnormalities (e.g. hemangioma), or a subcutaneous mass. Although neurological deficits are unusual in the newborn, motor or sensory disturbances in the legs or feet, or sphincter abnormalities occasionally may be detected. The closed defects are known as spina bifida occulta and spina bifida cystica.
|
NTD |
|---|
|
TopAbstractNeurulationNeural Tube Defects (NTD)NTDThe Aetiology Of NTDPrevention Of NTDFolateHomocysteine MetabolismDisturbed Homocysteine and...Summary and Concluding RemarksReferences |
|---|
The essential defect of anencephaly is failure of anterior neural tube closure. The most common variety of anencephaly includes involvement of the forebrain and variable amounts of upper brain stem. The exposed neural tissue is represented by a hemorrhagic, fibrotic, degenerated mass of neurons and glia with little definable structure. The frontal bones above the supraciliary ridge, the parietal bones, and the squamous part of the occipital bone are usually absent. This anomaly of skull imparts a remarkable froglike appearance to the patient when viewed face on. Onset of anencephaly is estimated to be no later than at the embryonic age of 24 days (34). Most children die before or during delivery. If they are born alive they can survive only for a couple of weeks. This disorder is relatively common, and epidemiological studies reveal striking variations in prevalence as a function of geographical location, sex, ethnic groups, race, season of the year, maternal age and nutritional state, social class, and history of affected siblings (38–41).
The essential defect in myeloschisis is failure of posterior neural tube closure. A neural plate-like structure involves large portions of the spinal cord and appears as a flat, raw, velvety structure with no overlying vertebrae or dermal covering. Onset is no later than at 24 days of embryonic development (34). Most of these infants are stillborn and merge with the category of more restricted defects of neural tube closure, i.e., meningo(myelo)cele.
Encephalocele may be envisioned as a restricted disorder of neurulation involving anterior neural tube closure. This defect occurs in the occipital region in 70% to 80% of the cases (36, 42–45). Less common sites include the frontal region where the encephalocele may protrude into the nasal cavity. Least common lesion sites include the temporal and parietal region (46). The neural tissue in an encephalocele usually connects to the underlying central nervous system through a narrow neck of tissue. As many as 50% of cases are complicated by hydrocephalus (47). Anomalies of venous drainage occur in about one-half of the patients and must be considered in surgical approaches to these lesions (48). Onset of the most severe lesions is probably no later than the approximate time of anterior neural tube closure (26 days) or shortly thereafter. Later times of onset are likely for the lesions that involve primarily or only the overlying meninges or skull (38).
The essential defect in meningo(myelo)cele is restricted failure of posterior neural tube closure. The occurrence of approximately 80% of all lesions in the lumbar region may reflect the fact that this is the last part of the neural tube to close (36). The neural lesion is represented by a neural plate or abortive neural tube-like structure in which the ventral half of the cord is relatively less affected than the dorsal. The axial skeleton is uniformly deficient, and an incomplete, though variable, dermal covering is present. The defects of the spinal column consist of a lack of fusion or an absence of the vertebral arches resulting in bilateral broadening of the vertebrae, lateral displacement of pedicles, and a widened spinal canal. The caudal extent of the vertebral changes is usually considerably greater than the extent of the neural lesion. The large majority of the lesions is associated with dorsal displacement of the neural tissue, such that a sac is created on the back. This kind of NTD is subdivided in two categories depending on the content of the sac. Saccular enlargements protruding through osseous defects of the vertebral column that contain anomalous meninges and spinal fluid but do not have neural elements affixed to their wall are called meningoceles. If the spinal cord or nerves are included in the saccular protrusion, one speaks of meningo(myelo)cele. Moreover, these structures frequently are "tethered" or fixed at their caudal end by fibrous bands, lipoma, extension of dermal sinus, or related lesions. This fixation is thought to impair normal mobility and functions such as bladder problems (incontinence).
Onset of meningo(myelo)cele is probably not later than at the embryonic age of 26 days, although this is a controversial point (34). Meningo(myelo)cele and its variants represent the most important examples of faulty neurulation since affected infants usually survive. The major clinical features relate primarily to the nature of the primary lesion, the associated neurological features, and hydrocephalus. Most patients with low lesions will be able to walk unaided, whereas those with higher lesions usually are wheelchair-dependent for at least a major portion of their activities.
Occult dysraphic states represent disorders of caudal neural tube formation, i.e. the development of the lower and sacral and coccygeal segments. The occult defects are limited to the posterior neural arches, laminae, and the spines.
If the anomaly is not visible externally, this defect is referred to as spina bifida occulta. Often this abnormality is so well concealed that it remains undetected for years, therefore the term "occult." With the occult dysraphic states, the neural lesion is often rather subtle and the major overt abnormality involves the vertebrae or the overlying dermal structures or both. The most common clinical presentations for occult dysraphic states later in infancy include delay in walking, asymmetry of legs or abnormalities of feet, and pain in the back or lower extremities. In the older child or adolescent, the major clinical features are gait disturbance, development of a foot deformity, and scoliosis.
|
The Aetiology Of NTD |
|---|
|
TopAbstractNeurulationNeural Tube Defects (NTD)NTDThe Aetiology Of NTDPrevention Of NTDFolateHomocysteine MetabolismDisturbed Homocysteine and...Summary and Concluding RemarksReferences |
|---|
Spontaneous-aborted affected embryos are excluded from these numbers, although in these fetuses the frequency of NTD is about 10 times higher than observed at birth. The prenatal mortality rate of NTD-affected embryos was reported to be 98.4%, and most of them (93%) did not develop beyond embryonic stage (50). It is therefore likely that the prevalence of NTD after neurulation is 10 to 50 times higher than at term, which implies that immediately after neurulation, one in 50 up to one in 10 embryos are affected.
A prominent and steady decline in birth prevalence rates of NTD in both the United States and Great Britain has been observed (41, 51–54). One explanation for these observations is the introduction of prenatal diagnosis in developed countries. In Australia, the birth prevalence has declined by 84%, which is attributed entirely to prenatal diagnosis and termination of pregnancy (55). On the other hand, some authors reported an additional decline in prevalence of NTD that is independent of prenatal diagnosis (57), which is reminiscent of the peaks and troughs in frequency of NTD that occurred in the early decades of the 20th century (57). Furthermore, the decline is apparent also in the Republic of Ireland where there is neither prenatal diagnosis nor legal termination of pregnancy. Thus, for reasons poorly understood, NTD are occurring less frequently than before (58).
Neural tube formation is a multifactorial process determined by both extrinsic and intrinsic factors. Therefore, NTD will be of multifactorial origin, involving both genetic and environmental factors. As shown below there are now many recognized causes of NTD; some are genetic and others are environmental. However, over 90% of the NTD cases still have an unknown etiology. Therefore, further investigations in the etiology of NTD are necessary to come to an understanding of the underlying cause of NTD. This may result in better prenatal diagnosis and prevention of NTD.
Genetic Factors and the Etiology of NTD.
Factors establishing the genetic role in several NTD forms include: (i) sex differences in the birth prevalence rates; (ii) ethnic differences that persist after geographical migration; (iii) increased prevalence with parental consanguinity; (iv) increased rate of concordance in monozygotic twin pairs; and (v) increased prevalence in siblings (as well as in second-degree and, to a lesser extent, third-degree relatives) and in children of affected patients (51, 52, 59–67).
Recognized causes of NTD include multifactorial inheritance, single-gene mutations (e.g. the autosomal recessively inherited Meckel's syndrome), and chromosomal abnormalities (e.g. trisomies 13 and 18) (52, 60, 68). Of these causes, the vast majority of cases are encompassed within the group in which NTD is the only major congenital abnormality, and inheritance is multifactorial, i.e., dependent upon a genetic predisposition that is polygenic and influenced by minor additive genetic variation at several gene loci (61). Upon this genetic background, environmental influences may play an important role.
Environmental Factors and the Etiology of NTD.
Apart from folate/folinic acid status, which will be discussed later, some possible environmental influences are diabetes, hyperthermia, use of specific teratogens like aminopterin, thalidomide, valproic acid, and other anti-epileptic medications, alcohol, and/or professional occupation. In addition, several environmental factors such as geography, month of conception, epidemic trends, maternal age, birth order, socioeconomic class, and maternal diet and zinc status contribute to increased risk (69–71). Particularly potent data do suggest that environmental influences relate to long-term trends in incidence, i.e., in the northeastern United States an epidemic period could be defined between approximately 1920 and 1949, with a peak between 1929 and 1932 (72). In the Netherlands there was a peak in the prevalence of NTD-affected offspring after the Hunger Winter of 1944–1945; during this period in the Second World War there was a major shortage of food (73). This observation suggests that there is an involvement of a nutritional component in the etiology of NTD.
|
Prevention Of NTD |
|---|
|
TopAbstractNeurulationNeural Tube Defects (NTD)NTDThe Aetiology Of NTDPrevention Of NTDFolateHomocysteine MetabolismDisturbed Homocysteine and...Summary and Concluding RemarksReferences |
|---|
The possibility that folate was specifically linked to NTD in humans was first reported by Hibbard (76). In a retrospective study he observed that women who had pregnancies associated with fetal malformations had a higher incidence of aberrant folate metabolism. He used a formiminoglutamate- (FiGlu) function test, which is based on the increased urinary excretion of FiGlu after histidine loading, because folate deficiency leads to a decreased conversion of FiGlu into glutamic acid. Hibbard and Smithells subsequently repeated this finding in a separate group of mothers who had had a malformed child. From this study onwards, a key role of folate in preventing NTD has been suggested (77).
The early epidemiological studies were mostly focused on the etiology of NTD; however, over the last 10 to 20 years the emphasis of these studies has shifted toward an evaluation of the efficacy of periconceptional vitamin administration, in particular folate, in preventing the development of NTD. The incentive leading to this shift was a study by Smithells and coworkers (78). They measured the first trimester blood vitamin levels in women who had a baby with NTD, and observed that red blood cell folate and leukocyte ascorbic acid levels were significantly lower when compared to mothers without NTD-affected offspring (78). These women had reduced red blood cell folate levels, but no decreased serum folate levels. Red blood cell folate is used as an index of folate stores since red blood cells have a life span of 120 days, whereas serum folate reflects recent dietary intake (79). Therefore, Smithells (78) data suggest that folate stores were low in the women with NTD pregnancies, even though their recent meals may have contained a sufficient amount of the vitamin. This study resulted in the hypothesis that periconceptional intake of vitamins might protect against NTD offspring (80). This observation led to an increased interest in nutritional factors in the etiology of NTD and was the starting point of many studies involving the metabolic folate pathways in families with NTD offspring.
Studies on diet in relation to pregnancy outcome showed that, in general, poor diet in the early months of pregnancy was associated with NTD offspring (81). There are also reports of a higher birth prevalence of NTD in lower socioeconomic groups, as well as in infants conceived in early spring, when fresh foods are less available. In 1991 there was a report of an almost 3-fold increase in NTD after a hurricane in Jamaica which destroyed the island's vegetation (82).
Recurrence and Occurrence Studies: Prevention of NTD with Adequate Folic Acid Intake.
Employing this background information, two different types of studies were carried out. One type intended to assess the specific effect of folate supplementation, and the other type intended to establish the effect of multivitamin supplementation. In the main, women who already had NTD-affected pregnancies were examined since they have an increased risk of another affected pregnancy. This risk is about one in 30, but if they have had two affected children, then the risk is further increased to one in 10, and after three, it is over one in five (83). In normal pregnancies this risk is about 1 to 2 in 1000.
Laurence and coworkers (84) studied the effect of a 4-mg folic acid supplementation before and during early pregnancy on the recurrence of NTD in a small-randomized trial. They showed a drop in NTD recurrences in folate users compared to nonusers. However, these studies have been criticized, mostly because of the small numbers (85, 86). The biggest criticism of the Laurence et al. (84) study was that two women in the folic acid treatment group had NTD-affected children. The study only became significant by retrospectively shifting them to noncompliant status, which was very unsound scientifically. The effect of multivitamin supplementation before and during early pregnancy on recurrence of NTD was studied by Smithells and colleagues (87–89) in women with a history of one or more NTD-affected pregnancies. The multivitamin supplement contained folate, riboflavin, ascorbic acid, and vitamin A. The obtained results were striking, and they were the first who reported primary prevention of NTD by periconceptional intake of a multivitamin preparation. This study has been criticized because of a selection bias; the case and control groups were not entirely comparable (85, 86). Several groups repeated these studies and showed a likewise effect of multiple vitamins (90, 91), or of folate (92) on the prevention for the recurrence of NTD.
Although the results of these early studies seemed promising, there was still doubt about the accurateness of the data and the role of folate versus a multivitamin supplement in the observed protective effect. Therefore, the British Medical Research Council performed a multicenter study (93). This is the largest and most important randomized trial examining the effect of periconceptional folate and multivitamin supplements in about 1200 high-risk mothers who have already had a NTD-affected child. These women were randomly assigned to four groups allocated to receive the following regimens of supplementation. Group one received daily 4 mg of periconceptional folic acid; group two received the same, but additionally a multivitamin supplementation; group three received the vitamin supplementation without folate; and the final group received a placebo containing only minerals. This study showed that folic acid alone was as good at preventing recurrences of NTD as the multivitamin plus folate. The recurrence of NTD pregnancy was reduced by 72% if compared with placebo-treated women. Vitamins without folic acid and minerals alone were ineffective in preventing NTD. The results were decisive in demonstrating the preventive effect and the specific role of folate (versus other components of the previously used multivitamin preparations) in prevention of NTD.
Only 5% of all infants with NTD are born to women who have previously had an affected child. It is likely that folate therapy could also prevent a substantial part of the other 95% of NTD cases, which are the first occurrence of an affected member in a family. Therefore, occurrence studies have also been designed to evaluate the effect of maternal periconceptional folic acid supplementation in families without a previous child affected with an NTD. The largest and most important randomized-controlled study of prevention on the first occurrence of NTD by vitamins was performed by Czeizel and Dudas (94) in Hungary. This study lasted eight years and involved more than 4000 women contemplating a pregnancy. These women were subdivided in two groups: one received a multivitamin containing 0.8 mg of folic acid, 11 other vitamins, and trace elements, and the other group received a placebo multimineral containing only the trace elements. The results showed six children with NTD in the latter group and none in the first group. This study, also referred to as the Budapest trial, demonstrated a complete prevention of the first occurrence risk of NTD due to periconceptional folic acid use by the mother.
Several other groups studied the first occurrence of NTD and likewise showed an effect of multiple vitamins containing folate (95–98), or folate (96, 99, 100) on the prevention of the first occurrence of NTD. In contrast to these studies, one major study has failed to find a preventive effect of dietary multiple vitamins and folate. This study was based on a questionnaire concerning the pregnancy outcome and the use of periconceptional multivitamins (101). The negative outcome of this study could be due to misclassifications of the users and nonusers of multivitamins.
Both the MRC trial and the Budapest trial undoubtedly showed a reduction in the birth prevalence of NTD by folate (93, 94). Therefore, it is now generally accepted that periconceptional folate supplementation reduces the recurrence and occurrence risk of NTD. Since the last decade, the governments of several countries are encouraging women who are planning a pregnancy to take 0.4 to 0.5 mg of folic acid daily during the periconceptional period to prevent the occurrence, and even 4 to 5 mg of folic acid to prevent the recurrence of NTD (reviewed in Ref. 102). Nevertheless, public awareness of the benefits of folic acid is only very slowly increasing (103). Although the mean dietary folate intake in Europe is in line with the recommended daily folate intake, the desired dietary intake to prevent NTD is only attained by a small part of most European populations (104).
Several countries, like the Netherlands, advise a daily additional intake of 0.4 to 0.5 mg of folate during the periconceptional period until two to three months of pregnancy have passed. This additional folate intake can be achieved by intake of folate supplements, food fortified with folic acid, and consumption of folate-rich foods. The latter manner is, however, not as effective as the former two (105). In the United States, the government decided in 1993 to fortify cereals, grain, and flour with folic acid by adding 1.4 mg of folic acid/kg to increase folic acid intake in the general population. Although this fortification officially began on January 1, 1998, a lot of food manufacturers began fortifying foods before this date. The results of this food fortification on pregnancy outcome will become evident in coming years.
|
Folate |
|---|
|
TopAbstractNeurulationNeural Tube Defects (NTD)NTDThe Aetiology Of NTDPrevention Of NTDFolateHomocysteine MetabolismDisturbed Homocysteine and...Summary and Concluding RemarksReferences |
|---|
The natural form is referred to as folate (folacin), which occurs naturally as polyglutamate derivatives with the glutamate moieties linked via 
-carboxyl peptide bonds. Several dietary sources rich in natural folate include a wide variety of fruits and vegetables, particularly green leafy vegetables such as spinach, brussel sprouts, and turnip greens. Other foods rich in folate include potatoes, oranges, beans, yeast, and organ foods such as liver. Natural folate mainly consists of 5-methyltetrahydrofolate (5-MeTHF) and 10-formyltetrahydrofolate (10-formylTHF) in their polyglutamate derivatives. Both compounds are readily oxidized and the rates vary directly with oxygen concentration, temperature, alkalinity, exposure to light, and concentration of cupric and ferric ions. Therefore, a considerable amount of folate can be destroyed in cooking, processing, and storage.
The generic term folate includes both naturally occurring polyglutamates as the synthetic form, folic acid. The common feature of all folates is the p-aminobenzoicacid part of the molecule attached to the apterin-ring on the NH2 end, and one or more glutamic acids in a -amide linkage at the carboxyl end (Fig. 3). The active center of folate is between the N5 and the N10 site. Folate derivatives are formed by different one-carbon subgroups, which are added to the active site (Fig. 3). Essentially, tetrahydrofolate (THF) is carrying a one-carbon unit present as formate in its most oxidized form and as methyl in its most reduced form; all of these one-carbon subgroups can be converted into each other.
|
). Folate is also indirectly a methyl donor in many methylation reactions via S-adenosylmethionine (AdoMet), for example, in the regulation of gene expression. Thus, folate is directly or indirectly essential for cell function, division, and differentiation. Acquisition of folate, therefore, is critically important to the viability of proliferating cells. The shutdown of DNA synthesis and AdoMet synthesis arising from folate deficiency perturbs the cell cycle and could lead to premature cell death. Because eukaryotic cells are unable to synthesize the folate structure de novo, folate is an essential nutrient. Thus, mammals are dependent on transport systems for uptake of folate compounds from the environment.
|
. Folate acts as donor and acceptor of one-carbon units in a variety of critical enzymatic reactions involved in one-carbon metabolism. The one-carbon units are principally derived from the ß-carbon of serine, but also from glycine, methyl- and dimethylglycine, formate, and histidine (106) (Fig. 4). One-carbon units are thus obtained from THF-mediated reactions, which are required for several major cellular processes like nucleic acid biosynthesis, protein biosynthesis, amino acid metabolism, methyl-group biogenesis, and vitamin metabolism (reviewed in Refs. 107 and 108).
|
, reaction 1). SHMT is the major provider of one-carbon units in the cell, particularly in replicating cells. Serine can enter the mitochondria, where it is converted to formate, which reenters the cytoplasm and acts as a primary carbon donor (109). The glycine-derived one-carbon units are generated from the second carbon of glycine by the glycine cleavage system, which results in the formation of 5,10-MTHF (Fig. 4, reaction 2). Formate-derived one-carbon units are formed by the ATP-dependent enzyme formyl synthetase, which activates formate to 10-formylTHF (Fig. 4, reaction 3). One-carbon units thus enter the active pool of one-carbon at the level of 5,10-MTHF and 10-formylTHF. 10-FormylTHF and 5,10-methenylTHF are substrates for purine biosynthesis, while 5,10-MTHF is involved in thymidine biosynthesis. Apart from this role in the biosynthesis of purines and thymidine and, thus, DNA and RNA, the folates provide a source of methyl-groups for over 100 methyltransferase-catalyzed reactions. This is done by converting 5,10-MTHF to 5-MeTHF, which is used to methylate Hcy to methionine by the vitamin B12-dependent enzyme methionine synthase (MS) (Fig. 4, reactions 4 and 5). Methionine can be activated by ATP to AdoMet, the ultimate methyl-donor in the body.
An alternative one-carbon source is FiGlu (110). During the catabolism of histidine, a formimino-group is transferred to THF followed by the release of ammonia and by the generation of 5,10-methenylTHF by the two enzyme activities, glutamate formiminotransferase and formiminoTHF cyclodeaminase (Fig. 4, reaction 6 and Fig. 5). This pathway represents only a minor source of one-carbon and may exist only in liver and kidney. The enzymes seem to be absent in fibroblasts and blood cells. Excess one-carbon units are removed from the one-carbon pool by their oxidation to CO2 by formylTHF dehydrogenase (Fig. 4, reaction 7). This enzyme also catalyzes the hydrolysis of 10-formylTHF to THF and formate. Activity of this bifunctional protein is restricted to the liver (111). The function of the hydrolase activity is yet unclear; it may represent an additional mechanism for regeneration of the unsubstituted THF under conditions in which utilization of substituted folate for biosynthetic purposes is impaired (107).
Thymidine biosynthesis.
Folate is required for the synthesis of thymidylate. This reaction is catalyzed by thymidylate synthase and involves the addition of formaldehyde group to the 5-position of deoxyuridylate. In this reaction the one-carbon group of 5,10-MTHF is transferred to deoxyuridine monophosphate (dUMP), resulting in the formation of deoxythymidine monophosphate (dTMP) and dihydrofolate (DHF) (Fig. 4, reaction 8). Synthesis of deoxynucleotides, which is mediated by thymidylate synthase and ribonucleotide reductase, is considered to be the rate-limiting step in DNA synthesis. DHF formed in the thymidylate synthase reaction has to be reduced to THF before it can participate in one-carbon transfer reactions (Fig. 5). This reduction is catalyzed by dihydrofolate reductase (DHFR), an enzyme that also catalyzes the reduction of folic acid to DHF. Normally, folic acid is not found in nonsupplemented foods and the major role of DHFR appears to be to reduce DHF formed in the thymidylate synthase reaction.
The thymidylate synthase expression level is related to the replication state of a cell. A multi-enzyme complex called replitase is formed during the S-phase of the cell cycle. This replitase contains thymidylate synthase, DHFR, DNA polymerase, thymidine kinase, deoxycytidine monophosphate kinase, nucleoside diphosphate kinase, and ribonucleotide reductase (107).
Purine biosynthesis.
One-carbon units at the oxidation level of formate are utilized in the de novo purine biosynthesis. The C8 and C2 positions in the purine ring are derived from the folate one-carbon pool from 5,10-methenylTHF in a reaction catalyzed by glycinamide ribonucleotide (GAR) transformylase to FGAR and from 10-formyl-THF by formylTHF 5-amino-4-imidazolecarboxamide ribonucleotide (AICAR) transformylase to FAICAR, respectively (Fig. 4, reaction 9 and Fig. 5). The 10-formyl needed for purine biosynthesis can be either directly derived from the 10-formylTHF synthetase-catalyzed reaction (Fig. 4, reaction 3), or can be derived from the oxidation of 5,10-MTHF to 10-formylTHF catalyzed by the NADP-dependent MTHF dehydrogenase and methenylTHF cyclohydrolase (112) (Fig. 4, reactions 10 and 11). Any 5-formylTHF (leucovorin) is converted to 5,10-methenylTHF by methenylTHF synthetase (Fig. 4, reaction 12). In mammalian tissues the dehydrogenase, cyclohydrolase, and synthetase activities are catalyzed by a single trifunctional protein, methylenetetrahydrofolate dehydrogenase (MTHFD) (113).
Methyl group synthesis.
An important part of one-carbon utilization involves the reduction of 5,10-MTHF to 5-MeTHF by the enzyme methylenetetrahydrofolate reductase (MTHFR) (Fig. 4, reaction 4). This reaction is physiologically irreversible. The methyl group of 5-MeTHF is donated to Hcy resulting in methionine synthesis, which is catalyzed by MS (Fig. 4, reaction 5 and Fig. 5). This is the sole enzyme that is able to metabolize the methyl-group of 5-MeTHF. MS plays a major role in methyl-group metabolism, as it allows the reutilization of the Hcy backbone as a carrier of methyl-groups. This reaction channels the one-carbon units derived from formate and amino acids such as serine, histidine, and glycine into the methylation cycle, providing a methyl-group for the synthesis of AdoMet via methionine, and sequentially a methyl-group that is used by many essential methyltransferase enzymes.
Folate Absorption and Transport.
Dietary folate polyglutamates need to be converted to monoglutamates before they can be absorbed (114, 115). In the jejunum, polyglutamates are converted to monoglutamates by a conjugase. Two distinct forms of human pteroylpolyglutamate hydrolase conjugase have been described, one in the intestine, which is present in the brush border and acts at a neutral pH, and one with a less clear function within lysosomes. At this point, luminal pH is critical (116) and absorption is optimal at a pH of 6.0, which significantly decreases at a pH of 5.0 or 7.0. During absorption in the jejunum, the different monoglutamyl folates are converted to 5-MeTHF; however, it is currently unclear whether the conversion takes place primarily in the intestine or the liver, or in both organs (116). 5-MeTHF monoglutamate is the principal circulating form of folate and is transported across the plasma membranes of cells, and thus the principal form by which the tissues are supplied with folate (117). Transcellular folate transport systems include transport across the placenta, renal tubular cells, and the blood brain barrier.
Three major pathways have been observed that mediate folate transport across mammalian cell membranes (118). Inward transport of folate and their analogues cells can occur by carrier-mediated (119), as well as receptor-mediated (120), mechanisms or by passive diffusion. These different folate transport systems may not be operational in all cell types. The pathway for entry of folate is likely to be distinct in different cells, depending on the relative efficiency of carrier-mediated and receptor-mediated mechanisms, as well as on the intra- and extracellular folate concentration.
Carrier-mediated folate uptake.
Pteroylmonoglutamates can be transported by a carrier-mediated energy-dependent process. The carrier-mediated mechanism, or the reduced folate carrier (RFC), is an integral membrane protein that is primarily responsible for permeation of these compounds in tumor cells (119). This system has a markedly higher affinity for 5-MeTHF than for PteGlu and also accumulates methotrexate and other anti-folates. The RFC mainly mediates bidirectional fluxes of reduced folates and antifolates (121). Transmembrane 
-helices of the RFC are believed to form channels through which substrates pass (122). The RFC operates at relatively high folate concentrations and has been referred to as the "reduced folate methotrexate," the "high capacity/low affinity," or the "micromolar" folate transport system. The RFC is driven by anion gradients, and anionic exchange may be the mechanism for the transport process (123).
Receptor-mediated folate uptake.
The second system, the receptor-mediated folate transport, occurs via different isoforms of folate receptors (FRs) (118, 124–126). These FRs bind physiological levels of folate and have a high affinity for folate in the nanomolar range. Although these isoforms vary in their affinities for folate forms, in general they have a higher affinity for folic acid than for reduced folates like 5-MeTHF or 5-formylTHF. The FR was originally described as a folate-binding protein found in tissues and plasma, but it has been shown to be mainly a membrane protein anchored by glycosyl-phosphatidyl-inositol linkage. FRs are crucial to the assimilation, distribution, and retention of food folates and have been identified in various cells, extracellular fluids, and tissues in mammalians (127). FR expression is inversely regulated by the extracellular folate concentration. The receptor-mediated transport of 5-MeTHF appears to occur via typical endocytotic pathway involving endocytic vacuoles (128) or via a similar pathway involving caveolae, where the receptor recycles within the caveolae without dissociating from the plasma membrane (129). Caveolae are capable of transiently closing to form a membrane-bound compartment that protects FRs both from acid treatment and from anti-folate receptor IpG. The FRs probably function to concentrate 5-MeTHF at the cell surface and deliver the vitamin to a vesicle (124). They are highly clustered on the cell surface of folate-dependent tissue cells.
The FRs can be separated into soluble and membrane-bound FR forms. These forms are structurally related, but differ in function (123, 127, 130). The soluble FRs likely serve multiple functions; they afford a convenient mechanism for concentrating folate compounds, they protect the bound, reduced folates from oxidation, and finally, soluble FRs could act as a storage protein to conserve folates. However, the precise function of the soluble FR is yet unknown (130). The membrane FR primarily accumulates folate at the cell surface and mediates the transport of folate compounds into cells.
FRs are encoded by a family of genes on chromosome 11q13.3 through 11q13.5, where four FR genes and a pseudogene were found within a 140-kb region (131). The human isoforms of the FR are known as FR, FRß, FR, and FR' which have a tissue-specific expression (132, 133). It is believed that the FR is a secretory FR, the soluble form of the FRs (134). The FR' is a truncated form of FR probably formed by alternative splicing (134) or results from gene polymorphism (133). Thus, there are several FR isoforms with different relative affinities for folate and expression patterns, but their precise functions are still unclear
Maternal-to-fetal folate transport.
Pregnancy is the most common cause of megaloblastic anemia in women worldwide. Folate requirements increase 5- to 10-fold compared with nonpregnant women for growth of the fetus, placenta, and maternal tissues (130). The FRs play a major role in transplacental folate transport, and the placenta is known to contain both FR and FRß (134, 135). The maternal-to-fetal folate transfer process consists of two steps. The first step is the concentrative component: circulating 5-MeTHF is bound to placental FR on the maternally facing chorionic surface. In the second step the folates are transferred to the fetal circulation along a downhill concentration gradient. This is a continuous process assuring unidirectional transplacental folate transport (130). However, one must keep in mind that during the process of neurulation the placenta is not yet developed. The exact mechanism of folate transport to the fetus previous to placental transport is unknown, but is thought to involve a similar mechanism.
Folate Polyglutamates and Polyglutamation.
Folate polyglutamates structure and function.
Cellular folates exist primarily as poly--glutamate derivatives and should be considered as the normal substrates for the enzymes of one-carbon metabolism. Polyglutamate derivatives consist of a THF derivative, with from three to 11 glutamate residues linked as amides through the -carboxyl group. To describe accurately the number of glutamate residues, the nomenclature system is related to tetrahydropteroate (H4Pte), which has no glutamate residues. Thus, THF is called H4PteGlu, and the pentaglutamate form is H4PteGlu5. In addition to a varying number of glutamate residues, there are six different one-carbon derivatives of H4PteGlun. Two of these derivatives, 5-formino- and 5,10-methenylH4PteGlun, exist in low concentration and probably do not contribute significantly to the total intracellular pool of folate. The major forms of reduced folate in the cell are 10-formyl-, 5-formyl-, 5-methyl-, and 5,10-methylenePteGlun derivatives and H4PteGlun (136).
It was thought that polyglutamate derivatives were only storage forms of the vitamin. Now it is apparent that intracellular conversion of folates to polyglutamates is important for the normal function and regulation of the one-carbon metabolism. Folylpolyglutamates are as effective as, and in many cases even more effective than, pteroylmonoglutamates as substrates for the enzymes of one-carbon metabolism (107). Extension of the glutamate chain decreases Km values, but also causes a decrease in Vmax with chain lengths beyond the diglutamate level (137). Therefore, with most folates the diglutamate derivative is a more effective substrate than the monoglutamate, owing primarily to a decrease in Km value. Polyglutamate folates of a chain length equal or greater than three have much lower Km values for some of the folate-dependent reactions, allowing folate metabolism to progress at the low concentration of the folates present in the cells.
Polyglutamates are only poorly transported across cell membranes. Consequently, metabolism of pteroylmonoglutamates to polyglutamate forms allows the cell to concentrate folates at much higher levels than in the external medium. In tissues, a particular length usually predominates, but a distribution of different lengths is observed. The major polyglutamate species in human cells are hepta- and octaglutamates (137).
Folate polyglutamation by folylpolyglutamate synthetase.
Intracellular metabolism of folates to polyglutamates is performed by the enzyme folylpolyglutamate synthetase (FPGS) (124, 138, 139). This enzyme is present in most mammalian tissues and adds glutamate residues one at a time to folate molecules (107). FPGS forms a peptide bond between the gamma-carboxyl of the glutamate already present on the molecule and the alpha-amino group of the glutamate to be added and requires ATP for this reaction (see below).
 | (1) |
This gamma-glutamyl chain is resistant to digestion by common proteolytic enzymes and is hydrolyzed by specific conjugase enzymes. The chain length is influenced by the monoglutamate concentration in the cell, as well as the FPGS activity (140). The human FPGS is a monomeric low-abundance protein that utilizes THF and other folates as substrates with different affinities, but reacts poorly with folic acid and 5-MeTHF. Unsubstituted reduced folates are the preferred substrate for the mammalian FPGS. H2PteGlu (DHF) is the most effective monoglutamate substrate, followed by H4PteGlu (THF), while H4PteGlun derivatives are the most effective polyglutamate substrates (137).
Mammalian tissues contain cytosolic and mitochondrial FPGS isoenzymes (141), which are encoded by a single gene that is localized to chromosome 9q34.1 region. These isoenzymes are formed by alternative splicing (142, 143). Mitochondrial FPGS activity is required for folate accumulation by mitochondria. Specific activity of the mitochondrial enzyme is higher than the cytosolic enzyme, which may explain the longer folylpolyglutamate derivatives in this organelle. Monoglutamates are being transported into mitochondria before they are polyglutamated by cytosolic FPGS. There is an indication for competition for folate between folate transport into mitochondria and cytosolic FPGS activity. It has been suggested that oxidized monoglutamates are mitochondrial transport forms of folate and that reduced folates are not transported (144, 145). However, others suggested that reduced folates are also transported into mitochondria (146).
Regulation of the Folate One-Carbon Metabolism.
Folate one-carbon metabolism is complex (Fig. 5). Regulation of the one-carbon flux through acceptors and donors is regulated by compartmentation of the substrates, enzymes, and products. There are three types of intracellular compartmentation. One type is compartmentation within intracellular organelles. A second mechanism involves distribution of metabolites between free and protein-bound state. The third mechanism involves channeling of substrates through sequential enzyme reactions (108). Each of these serves to segregate the intermediates into distinct pools. At its simplest, folate exists as two pools: one small pool with rapid turnover that is composed mainly of the monoglutamyl forms of folate in plasma, and a larger slow-turnover pool of folates functionally trapped in tissues as polyglutamyl forms, many of which are noncovalently bound to proteins.
In addition, the one-carbon metabolism may be regulated by polyglutamation state by varying the glutamate chain length of folates in the cell under different physiological conditions such as infection, hormonal status, and nutritional conditions. Modulations of the glutamate chain length of folates have been observed in mammalian cells and tissues in response to folate, methionine, and vitamin B12 levels and to changes in growth rates (147). The lengths of the products are inversely dependent on the initial monoglutamate concentration. High H4PteGlu concentrations lead to synthesis of shorter polyglutamates (148). In terms of metabolic efficiency, this is understandable because monoglutamates and short polyglutamates can be used in all mammalian folate reactions, although generally less efficiently than longer polyglutamates. Thus, under conditions of folate excess, formation of long polyglutamates would be wasteful of both ATP and glutamate. In folate-depleted conditions, not only does polyglutamate formation increase retention of folates once transported, but also each folate molecule is a more efficient carrier of one-carbon units (147).
Conversions of folates to polyglutamates are required for their cellular retention (148). Factors that affect the expression of FPGS will thereby also regulate the level of folate in the cell. Folylpolyglutamates with longer chain length retain a higher affinity for the enzyme, but have little or no activity. This suggests that they can act as end-product inhibitors of the enzyme and lead to a steady-state folate concentration in the cell. The changes would be expected to occur only at a slow rate, which would limit their physiological usefulness. According to a second hypothesis, many of the changes in the activity of the FPGS could also be explained by substrate availability for FPGS instead of regulation of the activity by polyglutamation. It has been proposed (149) that the regulation of folate metabolism by means of polyglutamate chain length is secondary to the classical alterations in folate metabolism characterized by the activation and inhibition of folylpolyglutamates of a number of folate-dependent enzymes involved in one-carbon metabolism.
Compartmentation within intracellular organelles.
Intracellular compartmentalization of the folate pathway concerns the cytosol and mitochondria. Nuclei contain only very low levels of folates (108). It has been demonstrated that mammalian cells contain cytosolic and mitochondrial one-carbon donors and acceptors, generating one-carbon pools in both the cytoplasm and the mitochondria (Fig. 5). The folate-dependent enzymes SHMT, MTHFD, and FPGS are present in both the cytoplasm and the mitochondria. Three additional folate-dependent enzymes, the glycine cleavage system, dimethylglycine dehydrogenase, and sarcosine dehydrogenase are strictly mitochondrial (Fig. 5). This distribution of folates and folate-dependent enzymes in these compartments is consistent with the known roles of folate-mediated one-carbon metabolism in each (Fig. 5). In the cytoplasm, folate coenzymes participate in the biogenesis of purines and thymidylate and in methyl-group biogenesis. The interconversion of serine and glycine occurs in both compartments. In mitochondria, folate coenzymes are required for the formation of transfer RNA for organellar protein synthesis and catabolism of glycine, sarcosine, and dimethylglycine.
Compartmentation of metabolites between free and protein-bound state.
In one-carbon metabolism both monoglutamates in the plasma and polyglutamates in the cells are distributed between free and protein-bound state. In the serum, two-thirds of the 5-MeTHF is loosely bound to a nonspecific folate binder with a low affinity, i.e., albumine. The folate-binding proteins are, importantly, involved in compartmentalization of folates by their uptake of free folates. Three folate-binding proteins have been found in the cytosolic fraction and two in the mitochondrial fraction. Four out of these five proteins have been identified as enzymes involved in one-carbon metabolism (108). One of these is the glycine N-methyltransferase, which is one of the major cytosolic folate-binding proteins in liver. This enzyme is inhibited by the binding of 5-MeTHF (150). Thus, binding of folate intermediates to one of these folate-binding proteins can inhibit or stimulate their activity or the activity of other enzymes. These folate-binding proteins bind about 60% of the total cytosolic folates and about 20% of the total mitochondrial folates in liver.
Compartmentation by channeling of folate substrates.
Many enzymes of one-carbon metabolism form protein complexes that enhance channeling of substrates through sequential enzyme reactions (107, 108). Channeling of folate was demonstrated for the first time in the three-functional MTHFD protein. Substrate channeling through coupled-enzyme reactions provides a dynamic microcompartmentation in which reaction intermediates are functionally isolated from those in the bulk phase of the compartment. Substrate channeling offers a number of potential kinetic and regulatory advantages. High metabolic rates can be obtained at low substrate concentrations since reaction rates are independent of bulk phase substrates (108). Reaction intermediates are isolated from competing reactions and unstable intermediates may be protected. Folylpolyglutamate substrates are channeled from active site to active site in multifunctional proteins or protein complexes without release of the intermediate product, a phenomena that is not observed with monoglutamate substrates. Substrate channeling of folate coenzymes in several folate-dependent reactions is greatly facilitated by the longer glutamate-chain length. Channeling by MTHFD was more efficient with the triglutamate substrate than with the monoglutamate. Thus, polyglutamates may play a role in maintaining specific protein-protein interactions (151).
Proposed Protective Mechanism of Folate on Preventing NTD.
Folate intake is an important environmental factor in the etiology of NTD. However, it is not known how the administered folate works. It could be overcoming a folate deficiency or a metabolic disturbance in the folate metabolism. A folate deficiency can occur due to an inadequate dietary intake, malabsorption, altered hepatic and peripheral metabolism, or an increased elimination of folate (152). The preventive effects of additional folate intake could be working at the level of the mother, at the level of the embryo, or even at both.
In an Irish study, an inverse relationship between red blood cell folate levels and the risk of NTD offspring was found, and the lower the red blood cell folate levels the higher the risk (153). Estimates have been made on the effect of additional folic acid intake on the red blood cell folate levels (154). This study gives a model for estimating the risk of having an NTD-affected pregnancy on the basis of maternal red blood cell folate levels. It was estimated that women with red blood cell folate levels above 1292 nmol/L have a 48% reduction in the risk of having a NTD pregnancy. These folate levels can be achieved by an additional intake of 0.4 mg/d.
Studies on the folate status of women who have had NTD offspring are not conclusive. Some of these women have low folate levels (78). More recent studies report nondeficient folate levels in women with NTD-affected pregnancies, although some were in the lower normal range (155–158). Overall, there is a trend for such women having slightly lower folate levels than control women. These lowered folate levels could be due to a lower intake of folate via the diet. However, Yates et al. (159) demonstrated an association between NTD births and low levels of maternal red cell folate, which could not be attributed entirely to lower dietary intake of folate. Schorah et al. (160) hypothesized that the preventive effect of folate could be due to an increased folate requirement of women genetically predisposed to have an infant affected with a NTD. A related hypothesis is that the absorption of folic acid is reduced in women with a history of NTD-affected offspring (99). These women may be inefficient in converting dietary folate into blood folate stores and thus may secondarily have an increased requirement for folic acid (161). Several other studies, however, showed that there is no evidence for a defect in the absorption of folate in women with NTD-affected offspring (162, 163). Finally, it is suggested that folic acid may overcome a metabolic disturbance of folate-related metabolic pathways (164). They showed that the methyl group of 5-MeTHF is more slowly incorporated into trophoblast DNA of NTD-affected fetuses than from controls. Lucock et al. (165) showed that women with two NTD-affected pregnancies needed a higher dietary folate intake to achieve the same 5-MeTHF concentrations as controls. This indicates a disturbance in the uptake or utilization of 5-MeTHF and therefore in folate metabolism. Also an impaired regeneration of THF is observed in mothers of a child with spina bifida (166).
One of the functions of folate is to act as a substrate for some of the enzymes involved in the de novo DNA synthesis, a process that is essential to the developing embryo. Via Hcy to methionine remethylation folate is also involved in methylation reactions. Therefore, Hcy levels could function as a marker of an impaired folate metabolism. The developmental genes are transcription factors that are in part regulated by means of methylation. A defective folate metabolism or folate shortage in the mother may also lead to a shortage of folate in the developing embryo. This could result in a defective DNA synthesis or an impaired transcription of genes involved in the neurulation process. Additional folate intake may overcome an impaired DNA synthesis or DNA methylation, or impaired methylation of other molecules such as receptors, etc.
|
Homocysteine Metabolism |
|---|
|
TopAbstractNeurulationNeural Tube Defects (NTD)NTDThe Aetiology Of NTDPrevention Of NTDFolateHomocysteine MetabolismDisturbed Homocysteine and...Summary and Concluding RemarksReferences |
|---|
) will be given below. Hcy does not occur in the diet, but is an amino acid that is formed by the demethylation of methionine. Dietary methionine is necessary for the normal growth and development of mammals because methionine is an essential amino acid. Two reactions compete for the available amino acid: protein synthesis and the synthesis of AdoMet by means of methionine adenosyltransferase (MAT).
|
